Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

835
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
835
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

2.5K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.5K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

2.9K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.9K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

2.2K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.2K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

4.0K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fluorogenic probes for intracellular copper detection and the study of cuproptosis.

Methods in cell biology·2026
Same author

Investigation of a GPC1-targeted and LIFU-responsive nanoplatform with ADV effect for visualized chemo-sonodynamic therapy against pancreatic ductal adenocarcinoma.

Journal of cancer research and clinical oncology·2026
Same author

Expressive writing intervention on optimism and coping modes of newly diagnosed people with human immunodeficiency virus: A randomized controlled trial.

Medicine·2026
Same author

Pan-genomic and pan-transcriptomic integration unveils evolutionary dynamics and regulatory diversification of the WRKY gene family in Camellia sinensis.

BMC plant biology·2026
Same author

Effects of preoperative anti-PD-1 therapy on intraoperative and postoperative analgesia in patients undergoing radical esophagectomy: a retrospective cohort study.

Scientific reports·2026
Same author

Formulation-dependent kinetics of <i>Lacticaseibacillus paracasei</i> Zhang in mice.

Microbiology spectrum·2026

Related Experiment Video

Updated: Mar 19, 2026

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats
05:12

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats

Published on: February 14, 2022

3.9K

Vericiguat Alleviates Atrial Electrical and Structural Remodeling in Rats with Atrial Fibrillation.

Xia Zhang1, Yubing Wang1, Liangchen Shen1

  • 1Department of Cardiovascular Medicine, Affiliated Hospital of North Sichuan Medical College, Nanchong, China.

Anatolian Journal of Cardiology
|March 17, 2026
PubMed
Summary

Vericiguat treatment effectively reversed atrial remodeling and fibrosis in a rat model of atrial fibrillation (AF). This suggests vericiguat may be a potential therapeutic agent for managing AF progression.

More Related Videos

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation
08:56

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation

Published on: September 24, 2021

3.2K
High-Resolution Endocardial and Epicardial Optical Mapping in a Sheep Model of Stretch-Induced Atrial Fibrillation
09:17

High-Resolution Endocardial and Epicardial Optical Mapping in a Sheep Model of Stretch-Induced Atrial Fibrillation

Published on: July 29, 2011

15.3K

Related Experiment Videos

Last Updated: Mar 19, 2026

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats
05:12

Transesophageal Atrial Burst Pacing for Atrial Fibrillation Induction in Rats

Published on: February 14, 2022

3.9K
Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation
08:56

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation

Published on: September 24, 2021

3.2K
High-Resolution Endocardial and Epicardial Optical Mapping in a Sheep Model of Stretch-Induced Atrial Fibrillation
09:17

High-Resolution Endocardial and Epicardial Optical Mapping in a Sheep Model of Stretch-Induced Atrial Fibrillation

Published on: July 29, 2011

15.3K

Area of Science:

  • Cardiology
  • Pharmacology
  • Molecular Biology

Background:

  • Atrial fibrillation (AF) pathogenesis involves progressive atrial structural remodeling, including fibrosis and electrical abnormalities.
  • Vericiguat's efficacy in heart failure (HF) suggests potential cardioprotective roles, but its impact on AF is not well understood.

Purpose of the Study:

  • To investigate the cardioprotective effects of vericiguat in a rat model of AF.
  • To assess vericiguat's impact on atrial remodeling and molecular markers associated with AF.

Main Methods:

  • A Sprague-Dawley rat model of AF was utilized, with rats randomly assigned to control, AF, or vericiguat-treated groups.
  • Echocardiography, histological assessments, and quantification of biomarkers (NT-proBNP, Collagen I, CaMKII, Cx43, ATG7, P62, LC3II/I) were performed on left atrial tissue.

Main Results:

  • AF rats showed atrial enlargement, increased myocardial fibrosis, and altered molecular markers compared to controls.
  • Vericiguat treatment reversed these pathological changes, normalizing biomarker levels and reducing fibrosis.

Conclusions:

  • Vericiguat attenuates atrial remodeling and AF progression.
  • The drug's effects are linked to the modulation of autophagy and suppression of fibrosis.